Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).

被引：3
|
作者：
Dougherty, Brian
Ledermann, Jonathan A.
Lai, Zhongwu
Robertson, Jane D.
Ho, Tony
Hodgson, Darren R.
O'Connor, Mark J.
Fielding, Anitra
Hawryluk, Matthew J.
Brennan, Tim
Yelensky, Roman
Sun, James
Barrett, J. Carl
机构：
[1] AstraZeneca, Waltham, MA USA
[2] UCL, Inst Canc, London, England
[3] AstraZeneca, Macclesfield, Cheshire, England
[4] AstraZeneca, Wilmington, DE USA
[5] Fdn Med Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5536
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
    Gourley, Charlie
    Friedlander, Michael
    Matulonis, Ursula A.
    Shirinkin, Vadim
    Selle, Frederic
    Scott, Clare L.
    Safra, Tamar
    Fielding, Anitra
    Rowe, Philip
    Ledermann, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
    Matulonis, Ursula
    Friedlander, Michael
    Du Bois, Andreas
    Gourley, Charlie
    Vergote, Ignace
    Rustin, Gordon J. S.
    Scott, Clare L.
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    McMurtry, Emma
    Spencer, Stuart
    Mann, Helen
    Parry, David
    Ledermann, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
    Friedlander, M.
    Gourlety, C.
    Matulonis, U.
    Shirinkin, V.
    Selle, F.
    Scott, C.
    Safra, T.
    Fielding, A.
    Rowe, P.
    Ledermann, J. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 13 - 13
  • [4] CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
    Friedlander, M.
    Gourley, C.
    Matulonis, U.
    Shirinkin, V.
    Selle, F.
    Scott, C.
    Safra, T.
    Fielding, A.
    Rowe, P.
    Ledermann, J. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1942 - 1943
  • [5] Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
    Ledermann, Jonathan A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon J. S.
    Scott, Clare L.
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Macpherson, Euan
    Dougherty, Brian
    Juergensmeier, Juliane M.
    Orr, Maria
    Matulonis, Ursula
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Overall survival (OS) in patients (pts) with platinum sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.
    Ledermann, Jonathan A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon J. S.
    Scott, Clare L.
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela E.
    Fielding, Anitra
    Spencer, Stuart
    Rowe, Philip
    Lowe, Elizabeth S.
    Matulonis, Ursula A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial
    Ledermann, Jonathan A.
    Lortholary, Alain
    Penson, Richard T.
    Gibbs, Emma
    Provencher, Diane M.
    Bruchim, Ilan
    Huzarski, Tomas
    Barretina-Ginesta, Maria Pilar
    Sabbatini, Roberto
    Mileshkin, Linda R.
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Matsumoto, Koji
    Sonke, Gabe S.
    Mikheeva, Olga N.
    Kim, Jae-Weon
    Girotto, Gustavo Colagiovanni
    Denys, Hannelore
    Lowe, Elizabeth S.
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
    Ledermann, J. A.
    Harter, P.
    Gourley, C.
    Friedlander, M.
    Vergote, I. B.
    Rustin, G. J. S.
    Scott, C.
    Meier, W.
    Shapira-Frommer, R.
    Safra, T.
    Matei, D.
    Macpherson, E.
    Watkins, C.
    Carmichael, J.
    Matulonis, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
    Ledermann, Jonathan A.
    Pujade-Lauraine, Eric
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [10] Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.
    Cadoo, Karen Anne
    Simpkins, Fiona
    Mathews, Cara Amanda
    Kabil, Nashwa
    Bennett, James
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345